A population-based, cross-sectional study of patients referred to the Danish hospital system between 1985 and 2006 was conducted to evaluate the long-term outcome in Danish patients treated for multifocal motor neuropathy (MMN). Thirty-four MMN patients were identified, three had died of unrelated diseases, 10 were excluded, one did not reply to study request and 20 were included. The median disease duration was 24 years (interquartile range: 18.5-31.0).
| INTRODUCTION
Since the first description of multifocal motor neuropathy (MMN) in the late 1980s, six long-term studies that included patients treated with either intravenous immunoglobulin (IVIG) or a combination of IVIG and cyclophosphamide have been published. [1] [2] [3] [4] [5] [6] In these studies, the number of patients ranged from 10 to 88. The total disease duration at the last evaluation varied from 8 to 18 years, the treatment duration period being 5 to 11 years. [1] [2] [3] [4] [5] Two of the studies have used a consecutive follow-up design, 1, 4 but none of the studies included control subjects.
We conducted a population-based, cross-sectional study of the long-term outcome in Danish patients treated for MMN. In order to study patients with long disease duration, only patients with a first contact to a neurologist before 2007 were included.
| MATERIALS AND METHODS
The study is cross-sectional and population based with a search period from 2 January 2016 to 28 February 2018. All patients in Denmark
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fulfilling the EFNS/PNS criteria for MMN and treated with immune modulating therapy during the period 1 January 1985 to 31 Decenber 2006 were eligible. The study period was from 2 January 2018 to 30 August 2018. Exclusion criteria were concomitant disabling neurological or orthopedic disorders, diabetes mellitus, other neuropathies, chemotherapy, and age above 90 years. A blood sample was taken for exclusion of diabetes, B12 and folic acid deficiency, kidney disease, and human immunodeficiency virus infection.
To evaluate the scores of disability, neuropathy impairment, function, and quality of life a group of 24 healthy subjects matched with respect to age, gender, weight ,and height was included using the same exclusion criteria as for the MMN patients.
| Register search
The diagnostic codes DG61.8 (other inflammatory polyneuropathies) and DG61.9 (inflammatory neuropathy, unspecified), as well as the To evaluate the significance of MMN for mortality, deceased patients were identified in the Danish Register of Causes of Death.
The search through registers was conducted between 2 January 2016 and 28 February 28 2018.
| Patient examination
Patient records were reviewed by AA to find eligible MMN patients and to record disease details regarding onset, course, treatment, and lag-time from symptom onset until initiation of immunoglobulin therapy. All patients and control subjects were interviewed and examined 2012-58-0004) approved the protocol. All MMN patients and control subjects gave written informed consent.
| Evaluation of the primary end-points
Disability was scored using a self-reporting questionnaire, the Raschbuilt Overall Disability Scale for Multifocal Motor Neuropathy (MMN-RODS), evaluating limitations of physical activity and social participation at scores ranging from 0 (most severe disability) to 50 (no disability). 7 Neurological impairment was rated using the neuropathy impairment score (NIS, 0: no impairment, 220: maximum impairment) assessing 21 pairs of muscle groups, five pairs of deep tendon reflexes, and four sensory modalities, as described elsewhere. 8 Mean isokinetic strength (IKS) at the elbow, wrist, knee, and ankle was evaluated either at the weakest side or in case of equal strength at a random side using dynamometry (Biodex System Pro 4/3; Biodex Medical Systems Inc., Shirley, New York). 9 Normalized strength was expressed as a ratio between the measured and predicted value of each muscle group, the latter being obtained from data of 178 healthy subjects.
9,10
Using a hand-held dynamometer (Jamar; Sammons Preston Roylan, Chicago, Illinois), grip strength was measured three times at each side, the mean of the maximum values at each side being used for evaluation.
11
The timed 25-foot walk (T25FW) was applied for evaluation of walking 12 and for dexterity a nine-hole peg test (9-HPT).
13
The EQ-5D-5 L-index value scale 14, 15 was utilized to evaluate quality of life.
| Evaluation of secondary end-points
For evaluation of combined weakness and ataxia, a six spot step test (SSST) in which five blocks are kicked away during walking was applied. 16, 17 For mood, social performance, self-rated quality of life, and severity of fatigue, we used the major depression inventory (MDI), 18 the 24-item social adjustment scale-self report: short (SAS-SR), 19 the EQ-5D-5 L-VAS 14,15 and the Fatigue Severity Scale (FSS) 20 as described elsewhere.
Aerobic capacity was evaluated by means of a 6 minutes submaximal cycle test. 21 The obtained heart rate was transformed to aerobic capacity using an Åstrand-Ryhming nomogram, a previously published formula and age correction following regression analysis. 
| Data availability statement
Anonymized participant data, study protocol, and statistical analysis plan can be shared following contact to the corresponding author.
3 | RESULTS
| National patient identification
The 
| Characteristics of MMN patients and control subjects
Characteristics of the 20 MMN patients and 24 control subjects are shown in Table 1 . Patients and controls did not differ with respect to 
| Primary end-point data
Values for the primary end-point variables are shown in Table 2 . The disability score, MMN-RODS, was reduced by 9% as compared to the control subjects. The NIS was moderately affected being 31 a.u. in patients as compared to 11 a.u. in controls. Median IKS was reduced by 29% in patients as compared to controls. The strength at the wrist and ankle was severely to moderately affected with a reduction of 38% and 24%, respectively. In comparison the strength at the elbow and knee was moderately to mildly reduced by 20% and 11%, respectively, the difference between the proximal strength at the elbow and knee vs the distal strength at the wrist and ankle being significant (P = 0.01).
The grip strength was severely impaired in patients being reduced by 56% as compared to controls. The T25FW was mildly prolonged by 13% and the EQ-5D-5 L-Index value impaired by 20%.
Regression coefficients following univariate regression analysis of the MMN-RODS and the NIS against the remaining primary and secondary end-points are presented in Table 3 . The NIS was related to primary end-points including the IKS, grip strength, and quality of life (Figure 2 ), whereas the MMN-RODS neither was related to the NIS nor any of the other primary end-points, except for being correlated to the quality of life following Spearman rank correlation test.
| Secondary end-points
Results for the secondary end-points are shown in Table 4 . The MMN patients were more fatigued according to the FSS questionnaire and performed the 9-HPT and SSST slower than the controls. Moreover, the self-rated quality of life, the EQ-5D-5 L-VAS score was reduced by 14%. The aerobic capacity, mood (MDI), social performance (SAS-SR-short) and the amount of weekly paid work did not differ between the patients and the control subjects. The regression coefficients showed that the NIS was related to 9HPT, SSST, and the self-rated quality of life, whereas the MMN-RODS was related to dexterity, mood, and the self-rated quality of life. 
| DISCUSSION
We performed a cross-sectional, population-based study on 20 treated
Danish MMN patients with a median disease duration of 24 years, the longest observation period hitherto reported. In the present study, the disease duration period was 24 years as compared to 8 to 18 years in previous studies, the treatment period being 14 years in our study as compared to 5 to 11 years. [1] [2] [3] [4] [5] The obtained results were compared to those of 24 matched control subjects, making it possible to evaluate the degree of impairment. Patients had a moderate to severe degree of long-term neurological impairment primarily affecting the distal musculature with severe impairment of hand and finger movements. Also, quality of life was mildly reduced with an increased degree of fatigue, but social performances were preserved. The impairment including muscular weakness was related to lag-time from start of symptoms to start of therapy. In the present study, MMN patients were moderately to severely impaired despite the majority received effective IVIG treatment. The median MRC was decreased by 8% in an outcome study of 88 patients, 1 while the mean MRC scores were reduced by 18% in a clinical and electrophysiological study of 20 patients, 6 by 6% in a case record review of 10 patients, 2 by 15% in a 8.2 year follow-up of 10 patients 3 and by 6% in a clinical and electrophysiological follow-up study of 11 patients. 5 Even though a direct comparison between the continuous variables used in our study and the ordinal variables used in previous studies is not possible, our observations seem to be in accordance with these other findings. The IKS was 29% weaker in the MMN patients than in control subjects. Since MMN is highly asymmetric and strength has been evaluated at the most affected side, our IKS value represents the manifestations of the disorder rather than the overall muscle performance. In the present study, the strength at the wrist and ankle were significantly more impaired than at the elbow and knee. This is in line with earlier observations, showing that MMN affects the strength more severely at distal than at proximal joints. 1 Moreover, attention should be drawn to the fact that the ankle plantar flexion was reduced by 23% in our MMN patients. Moderate impairment of the ankle plantar flexion is not easily appreciated in clinical settings and might affect walking and especially the running function.
The primary end-point that was the least impaired in the patients was the MMN-RODS. Moreover, the dispersion of the scores obtained in patients was low, the IQR being 5.5 at a 50-grade scale. In addition, following univariate regression analysis the MMN-RODS raw score was only associated to three end-point values, namely the self-rated quality of life, mood, and dexterity, while it was further associated to the examiner-rated quality of life and fatigue following non-parametric correlation analysis. It is possible that analysis using the nomogram for the Rasch transformation would strengthen the relationship between RODS and the various end points.
The most impaired primary variable was the grip strength. This is in contrast to the relative preservation of finger flexion strength observed in the present study and previously reported. 2 The explanation could be that flexion of fingers using a handheld dynamometer requires the application of extensional force at the wrist to counteract the secondary flexional force provided by the finger flexors.
All but one MMN patients were ambulatory without walking aids, but the T25FW and the SSST were both moderately impaired. The non-ambulatory patient could stand up and walk with assistance from two persons, only. The lack of ambulation was attributed to complete paralysis of both flexion and extension at the ankles, preventing stabilization of the feet. This patient was treated with azathioprine and had never received immunoglobulin treatment. The MMN patients were significantly more fatigued than the control subjects. This is in line with earlier observations in MMN 1 and in inflammatory neuropathies. 24 In general, it is recommended that fatigue should be assessed as part of the clinical evaluation in inflammatory neuropathy. 24 ,25 However, we were not able to demonstrate a relationship between fatigue and neurological impairment (NIS). Previous reports have shown that the degree of impairment and disability is associated with axonal loss and not with features of demyelination. 1, 6 It is, therefore, possible that fatigue might be a feature of the current level of inflammation rather than of the disease burden.
As for the primary end-points, the most impaired secondary endpoint (9-HPT) affected the hand function. This is in line with previous reports stating that MMN primarily affects distal parts of the limbs, especially the hand.
2 FIGURE 2 Univariate regression analysis of the neuropathy impairment score against four of the primary and secondary end-points with 95% confidence interval (gray shading) and prediction limits (area between dashed lines) The aerobic capacity, mood, social adjustment and amount of work did not differ between MMN patients and the controls. Both the objectively assessed and self-rated quality of life scores were, however, moderately affected in MMN patients compared to the control subjects. In addition, the MMN-RODS, which reflects home activities, was slightly but significantly impaired. These finding are in contrast to the moderate to severe impairments observed using other scales indicating that MMN patients are capable of maintaining a relatively normal life despite considerable impairment and function deficits.
In accordance with previous reports, the lag-time from disease onset until initiation of IVIG treatment was positively associated with neurological impairment evaluated by the NIS and IKS for patients of the same age. 1, 6 Moreover, in both these studies, the significant association persisted following regression against the duration of treatment. In the present study neither age nor duration of treatment had any significant association to NIS or IKS impairment following inclusion of lag-time until treatment initiation. In fact, the coefficient of determination, R 2 , for the multivariate regression analysis of lagtime before treatment initiation and age against the IKS was 0.61, with P-values for the regression coefficients of the lag-time and age being 0.002 and 0.3, respectively. Thus, most of the long-term variation of IKS for patients with the same age is explained by the lagtime before treatment initiation. Part of the impairment obtained in previous studies on MMN might well be explained by the long lagtime of several years before start of therapy. [1] [2] [3] [4] [5] [6] This explanation is supported by two previous reports 1, 6 as well as by the present study. All in all, the latency before treatment initiation seems to be an established prognostic factor for the long-term condition in patients with MMN.
Previous reports have described a decrease of muscle strength during IVIG-treatment. 3, 5 Although one of the studies reported an increase in administered IVIG dose throughout the follow-up period, 1 two studies reported no effect of duration of treatment. 1, 6 This is further supported by a clinical and electrophysiological follow-up study of more than 7 years, in which no clinical or electrophysiological deterioration took place throughout the treatment period. 2 As previously described, the latency until treatment initiation is predictive for the long-term outcome. Consequently, the application of the disease burden data in two subsets of patients with short and long latency would demonstrate a difference. The median latency until IVIG initiation in our patients was 7.0 years (2.5-11.5 years). Post hoc analysis dividing the patients into two groups showed that the median NIS in the short latency group with a latency of less than 7 years was Two of our patients had not received IVIG treatment for 3 years because of apparent disease inactivity. Moreover, two patients had at least once resumed regular treatment because of slowly deterioration after IVIG discontinuation. Two previous studies using systematic and consecutive inclusion of patients have reported that a few patients could discontinue IVIG therapy following partial remission. 1, 4 However, in all previous reports, the fraction of patients in sustained remission is small. Moreover, the indolent nature of MMN makes it difficult to appreciate a minor progression in patients apparently being in remission. Thus, it remains questionable to what degree MMN patients go into remission, if at all.
We have performed a cross-sectional study of MMN patients with the longest disease duration hitherto reported and compared the obtained values with those of control subjects. Our study shows that long-term patients with MMN have a moderate to severe degree of impairment and that the early initiation of IVIG treatment, hopefully, might reduce the disease burden.
